PUBLICATION
An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin
- Authors
- Gianoncelli, A., Bonini, S.A., Bertuzzi, M., Guarienti, M., Vezzoli, S., Kumar, R., Delbarba, A., Mastinu, A., Sigala, S., Spano, P., Pani, L., Pecorelli, S., Memo, M.
- ID
- ZDB-PUB-150904-6
- Date
- 2015
- Source
- BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 29(4): 285-300 (Journal)
- Registered Authors
- Keywords
- none
- MeSH Terms
-
- Epoetin Alfa/chemistry*
- Epoetin Alfa/pharmacology
- Epoetin Alfa/standards
- Recombinant Proteins
- Humans
- Biosimilar Pharmaceuticals/chemistry*
- Biosimilar Pharmaceuticals/pharmacology
- Biosimilar Pharmaceuticals/standards
- Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods
- Drug Approval
- Zebrafish/embryology
- Hematinics/chemistry*
- Hematinics/pharmacology
- Hematinics/standards
- Quality Control
- Chromatography, Reverse-Phase/methods
- Amino Acid Sequence
- Chromatography, High Pressure Liquid/methods
- Cell Proliferation/drug effects
- Cells, Cultured
- Animals
- PubMed
- 26334631 Full text @ BioDrugs
Citation
Gianoncelli, A., Bonini, S.A., Bertuzzi, M., Guarienti, M., Vezzoli, S., Kumar, R., Delbarba, A., Mastinu, A., Sigala, S., Spano, P., Pani, L., Pecorelli, S., Memo, M. (2015) An Integrated Approach for a Structural and Functional Evaluation of Biosimilars: Implications for Erythropoietin. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 29(4):285-300.
Abstract
Background Authorization to market a biosimilar product by the appropriate institutions is expected based on biosimilarity with its originator product. The analogy between the originator and its biosimilar(s) is assessed through safety, purity, and potency analyses.
Objective In this study, we proposed a useful quality control system for rapid and economic primary screening of potential biosimilar drugs. For this purpose, chemical and functional characterization of the originator rhEPO alfa and two of its biosimilars was discussed.
Methods Qualitative and quantitative analyses of the originator rhEPO alfa and its biosimilars were performed using reversed-phase high-performance liquid chromatography (RP-HPLC). The identification of proteins and the separation of isoforms were studied using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS) and two-dimensional gel electrophoresis (2D-PAGE), respectively. Furthermore, the biological activity of these drugs was measured both in vitro, evaluating the TF-1 cell proliferation rate, and in vivo, using the innovative experimental animal model of the zebrafish embryos.
Results Chemical analyses showed that the quantitative concentrations of rhEPO alfa were in agreement with the labeled claims by the corresponding manufacturers. The qualitative analyses performed demonstrated that the three drugs were pure and that they had the same amino acid sequence. Chemical differences were found only at the level of isoforms containing N-glycosylation; however, functional in vitro and in vivo studies did not show any significant differences from a biosimilar point of view.
Conclusion These rapid and economic structural and functional analyses were effective in the evaluation of the biosimilarity between the originator rhEPO alfa and the biosimilars analyzed.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping